Enavogliflozin

Names

[ Name ]:
Enavogliflozin

[Synonym ]:
D-Glucitol, 1,5-anhydro-1-C-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-4-benzofuranyl]-, (1S)-
(1S)-1,5-Anhydro-1-[7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1-benzofuran-4-yl]-D-glucitol

Biological Activity

[Description]:

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].

[Related Catalog]:

Research Areas >> Metabolic Disease

Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT

[Target]

SGLT2

[In Vitro]

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].

[References]

[1]. Daewoong speeds up developing antidiabetic Enavogliflozin

[2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin

[3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong's Enavogliflozin & Janssen Biotech's Golimumab Among Others - ResearchAndMarkets.com

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
666.1±55.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₄H₂₇ClO₆

[ Molecular Weight ]:
446.92

[ Flash Point ]:
356.7±31.5 °C

[ Exact Mass ]:
446.149628

[ LogP ]:
4.90

[ Vapour Pressure ]:
0.0±2.1 mmHg at 25°C

[ Index of Refraction ]:
1.666